SARS-CoV-2: Difference between revisions
From IDWiki
(→) |
No edit summary |
||
| Line 4: | Line 4: | ||
=== Epidemiology === |
=== Epidemiology === |
||
* First cases detected Dec 2019 related to likely exposure in wet market in Wuhan, Hubei, China |
|||
* Pandemic in 2020 |
|||
* Declared pandemic by WHO in 2020 |
|||
== Clinical Presentation == |
== Clinical Presentation == |
||
Revision as of 23:39, 15 March 2020
Background
Microbiology
- Coronavirus related to SARS-CoV
Epidemiology
- First cases detected Dec 2019 related to likely exposure in wet market in Wuhan, Hubei, China
- Declared pandemic by WHO in 2020
Clinical Presentation
- Incubation period 4-5 days on average, possibly as long as 14 days in some cases
- Main presenting symptoms were fever and cough
- Other symptoms include dyspnea, rhinorrhea, vomiting, diarrhea
Management
- Primarily supportive
- Investigational therapeutics include tocilizumab, lopinavir/ritonavir, and chloroquine
References
- ^ Louise Lansbury, Benjamin Lim, Vadsala Baskaran, Wei Shen Lim. Co-infections in people with COVID-19: a systematic review and meta-analysis. Journal of Infection. 2020;81(2):266-275. doi:10.1016/j.jinf.2020.05.046.
- ^ Scott Simpson, Fernando U. Kay, Suhny Abbara, Sanjeev Bhalla, Jonathan H. Chung, Michael Chung, Travis S. Henry, Jeffrey P. Kanne, Seth Kligerman, Jane P. Ko, Harold Litt. Radiological Society of North America Expert Consensus Document on Reporting Chest CT Findings Related to COVID-19: Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. Radiology: Cardiothoracic Imaging. 2020;2(2):e200152. doi:10.1148/ryct.2020200152.
- ^ Robert L. Gottlieb, Carlos E. Vaca, Roger Paredes, Jorge Mera, Brandon J. Webb, Gilberto Perez, Godson Oguchi, Pablo Ryan, Bibi U. Nielsen, Michael Brown, Ausberto Hidalgo, Yessica Sachdeva, Shilpi Mittal, Olayemi Osiyemi, Jacek Skarbinski, Kavita Juneja, Robert H. Hyland, Anu Osinusi, Shuguang Chen, Gregory Camus, Mazin Abdelghany, Santosh Davies, Nicole Behenna-Renton, Frank Duff, Francisco M. Marty, Morgan J. Katz, Adit A. Ginde, Samuel M. Brown, Joshua T. Schiffer, Joshua A. Hill. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. New England Journal of Medicine. 2021. doi:10.1056/nejmoa2116846.
